U.S., Sept. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07191379) titled 'Self-administered Subcutaneous Daratumumab in Patients With Multiple Myeloma' on Sept. 09.
Brief Summary: The main goal in this open label, phase four, prospective, non-randomized, sponsor-initiated multicenter feasibility study is to evaluate the feasibility and safety of self-administration of subcutaneously (SC) daratumumab in the patients with multiple myeloma in their own home. The study intervention is self-administration of SC daratumumab by the patient, thereby changing the administration from an outpatient setting to a home setting. To reduce potential bias, patients will function as their own controls by receiving alterna...